| TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade V Cervera-Carrascon, M Siurala, JM Santos, R Havunen, S Tähtinen, ... Oncoimmunology 7 (5), e1412902, 2018 | 115 | 2018 |
| Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus R Havunen, JM Santos, S Sorsa, T Rantapero, D Lumen, M Siurala, ... Molecular Therapy-Oncolytics 11, 109-121, 2018 | 61 | 2018 |
| Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity JM Santos, C Heiniö, V Cervera-Carrascon, DCA Quixabeira, M Siurala, ... Journal for immunotherapy of cancer 8 (1), 2020 | 56 | 2020 |
| Adenoviral delivery of tumor necrosis factor-α and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma M Siurala, R Havunen, D Saha, D Lumen, AJ Airaksinen, S Tähtinen, ... Molecular Therapy 24 (8), 1435-1443, 2016 | 52 | 2016 |
| Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy JM Santos, V Cervera-Carrascon, R Havunen, S Zafar, M Siurala, S Sorsa, ... Molecular Therapy 26 (9), 2243-2254, 2018 | 49 | 2018 |
| Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors V Cervera-Carrascon, DCA Quixabeira, R Havunen, JM Santos, ... Molecular Therapy-Oncolytics 17, 47-60, 2020 | 44 | 2020 |
| TNFa and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling C Heiniö, R Havunen, J Santos, K de Lint, V Cervera-Carrascon, ... Cells 9 (4), 798, 2020 | 39 | 2020 |
| CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy S Zafar, S Sorsa, M Siurala, O Hemminki, R Havunen, ... Oncoimmunology 7 (10), e1490856, 2018 | 33 | 2018 |
| Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor anti-PD-1 R Havunen, R Kalliokoski, M Siurala, S Sorsa, JM Santos, ... Cells 10 (2), 246, 2021 | 31 | 2021 |
| Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) cytokine re-programs the tumor microenvironment and confers enhanced tumor control DCA Quixabeira, S Zafar, JM Santos, V Cervera-Carrascon, R Havunen, ... Frontiers in Immunology 12, 674400, 2021 | 29 | 2021 |
| Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers J Santos, C Heiniö, D Quixabeira, S Zafar, J Clubb, S Pakola, ... Cells 10 (5), 978, 2021 | 29 | 2021 |
| A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma C Capasso, A Magarkar, V Cervera-Carrascon, M Fusciello, S Feola, ... Oncoimmunology 6 (9), e1319028, 2017 | 29 | 2017 |
| Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. V Cervera-Carrascon, R Havunen, A Hemminki Expert opinion on biological therapy 19 (5), 443-455, 2019 | 28 | 2019 |
| Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy JM Santos, R Havunen, M Siurala, V Cervera‐Carrascon, S Tähtinen, ... International Journal of Cancer 141 (7), 1458-1468, 2017 | 26 | 2017 |
| Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression TV Kudling, JHA Clubb, DCA Quixabeira, JM Santos, R Havunen, ... Oncoimmunology 11 (1), 2096572, 2022 | 25 | 2022 |
| Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition V Cervera-Carrascon, DCA Quixabeira, JM Santos, R Havunen, S Zafar, ... Oncoimmunology 9 (1), 1761229, 2020 | 25 | 2020 |
| Adenovirus encoding tumor necrosis factor alpha and interleukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer JHA Clubb, TV Kudling, C Heiniö, S Basnet, S Pakola, ... Frontiers in immunology 13, 794251, 2022 | 24 | 2022 |
| Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes S Zafar, DCA Quixabeira, TV Kudling, V Cervera-Carrascon, JM Santos, ... Cancer gene therapy 28 (5), 442-454, 2021 | 20 | 2021 |
| Enhanced stability and bioactivity of natural anticancer topoisomerase i inhibitors through cyclodextrin complexation V González-Ruiz, Á Cores, O Martín-Cámara, K Orellana, ... Pharmaceutics 13 (10), 1609, 2021 | 19 | 2021 |
| Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples S Zafar, S Basnet, IM Launonen, DCA Quixabeira, J Santos, O Hemminki, ... Human gene therapy 32 (3-4), 192-202, 2021 | 19 | 2021 |
